Dental pain has an unusual ability to shrink a person’s world. Eating, sleeping, speaking and concentrating can all become difficult when a tooth, jaw joint or oral tissue hurts. That makes dentistry an obvious place to ask whether cannabinoids might do more than reduce a pain score on a chart: could they also make treatment easier to live with?
A new 2026 literature review published in Revista Fitos takes that question seriously. Brazilian researchers examined the medical-cannabis literature relevant to dentistry, including work on orofacial pain, periodontal disease, bruxism, burning mouth syndrome and oral mucositis. Their conclusion was cautiously optimistic: cannabinoids have plausible therapeutic applications in dental care and may ultimately contribute to better clinical outcomes and patient quality of life. But the phrase “may ultimately” matters. This review did not itself test a treatment in patients, and it did not directly demonstrate an improvement in quality of life.
Key Takeaways
The review included 59 publications selected from 135 initially identified records and found the strongest clinical interest around pain, bruxism, temporomandibular disorders and inflammatory oral conditions. Some small randomized trials have produced encouraging results, including studies of CBD for acute toothache and muscle-related jaw pain. Yet the overall evidence remains mixed in quality: the review combines clinical and preclinical research, different cannabinoid products, different routes of administration and several very different dental conditions. Most importantly for the question of patient quality of life, the review did not pool validated quality-of-life measurements. Its findings support further clinical research, not the conclusion that medical cannabis is now a proven dental therapy.
Medical Cannabis in Dentistry and Patient Quality of Life: What the Review Found
The authors conducted what they describe as a narrative literature review covering research published from 2000 through 2025. Clinical and preclinical studies were eligible if they examined medicinal cannabis in a dental context and were peer reviewed in English or Portuguese. Publications focusing only on recreational cannabis were excluded.
The numbers give a useful sense of scale. Researchers initially identified 135 articles. After title and abstract screening, 32 were removed as duplicates or because they did not directly address dental applications. That left 103 papers for full-text assessment. Another 44 failed the inclusion criteria, producing a final set of 59 publications. There was therefore no single patient “sample size” for the review itself: its sample was 59 publications, ranging from laboratory experiments and literature reviews to relatively small clinical trials.
That distinction is important. A review of 59 studies can sound substantial, but 59 heterogeneous papers are not equivalent to one large clinical trial involving thousands of dental patients. The evidence is more like a box containing several different kinds of puzzle pieces. Some fit together; others address different pictures entirely.
There are also methodological reasons to be cautious. The methods section says the search used PubMed, SciELO and Cochrane, while the results section describes records identified through PubMed, SciELO, LILACS and Scopus. The paper says articles were assessed for methodological quality and clinical relevance but does not present a formal risk-of-bias instrument or a meta-analysis producing a pooled estimate of benefit. It is therefore useful as a broad map of the field rather than a definitive measurement of treatment effectiveness.
Where the Human Evidence Looks Most Interesting
Pain is the clearest reason dentistry has become interested in cannabinoids. The mouth and jaw contain dense sensory networks, and conditions such as pulp inflammation, temporomandibular disorders and neuropathic facial pain can be extremely difficult to manage.
One particularly relevant randomized placebo-controlled trial of CBD for acute dental pain enrolled 61 adults with moderate to severe toothache. Participants received a single dose of CBD at 10 mg/kg, CBD at 20 mg/kg or placebo and were followed for three hours. Both CBD groups experienced significantly greater reductions in pain than the placebo group, with maximum median pain reduction reaching 73% from baseline at 180 minutes in the published abstract. Sedation, diarrhea and abdominal pain occurred significantly more often in the CBD groups.
That is meaningful clinical evidence, but it is also highly specific evidence. The researchers used a pharmaceutical CBD preparation under controlled conditions. The trial did not test smoked cannabis, dispensary flower, a consumer CBD gummy or an unspecified “medical cannabis” product. Nor does one 61-person trial establish routine dental use.
Another randomized double-blind clinical trial published in 2024 focused on sleep bruxism and muscle-related temporomandibular disorders. Sixty patients completed the three-arm study. They received intraoral formulations containing 10% CBD, 5% CBD or placebo and were followed for 30 days. In the 10% group, pain measured on a visual analogue scale fell by 57.4%, muscle electrical activity by 42.1%, and the sleep-bruxism index by 51%. The 5% formulation produced a 40.8% reduction in pain.
Again, the signal is intriguing, but the study was small and short. Replication in larger, independent and longer trials would be necessary before researchers could know how durable the effect is, which patients are most likely to benefit and how the treatment compares directly with established approaches.
For broader context, The Cannex has previously examined the evidence around medical cannabis and chronic musculoskeletal pain. Pain research outside dentistry helps explain why cannabinoid therapies are attracting attention, but results from back, joint or muscle pain cannot simply be imported into dental practice.
Why the Mouth Is a Plausible Target for Cannabinoid Research
There is a biological reason researchers keep returning to this field. The body has an endocannabinoid system, a network of signaling molecules and receptors involved in processes such as pain, inflammation and immune responses. Think of it less as a single “cannabis receptor” and more as a communication system that happens to interact with compounds made by the cannabis plant.
The 2026 review notes that cannabinoid-related receptors and signaling have been identified in oral tissues including the mucosa, dental pulp, periodontal tissues, salivary glands and temporomandibular joints. That gives researchers plausible mechanisms for studying cannabinoids in pain and inflammation.
But biological plausibility is the beginning of a research story, not the ending. A receptor being present in gum tissue does not prove that applying CBD to the gums will prevent periodontitis, just as finding a lock does not prove that every key designed for it will open the door safely.
Some laboratory work has nevertheless produced interesting leads. The Cannex has covered research into CBD-containing mouthwash and oral inflammation as well as experimental work involving CBD-coated dentures and oral infection risk. These are useful examples of how cannabinoid science is expanding beyond systemic pain treatment into materials and topical oral care. They should not, however, be confused with evidence that ordinary commercial CBD products improve dental health.
The Patient Quality-of-Life Claim Needs More Care
This is where headlines can get ahead of the evidence.
The authors of the new review argue that integrating cannabinoids into dentistry could improve clinical outcomes and enhance quality of life during treatment. That is a reasonable hypothesis. Severe tooth pain can interfere with sleep and eating. Bruxism and temporomandibular pain can make speaking or chewing uncomfortable. Burning mouth syndrome can cause persistent distress despite the absence of an obvious lesion. A treatment that genuinely reduces those symptoms could logically improve daily life.
Yet the review did not enroll a group of dental patients, measure their quality of life before treatment, give them medical cannabis and then show that validated quality-of-life scores improved. Nor did it combine quality-of-life outcomes from the 59 included papers in a meta-analysis.
Instead, quality of life is partly an inference from improvements in outcomes such as pain, muscle tension, sleep-related bruxism and oral function. Those outcomes matter, but they are not interchangeable with a validated patient-reported quality-of-life measure.
That means the scientifically defensible conclusion is narrower than “medical cannabis boosts dental patients’ quality of life.” A better reading is that selected cannabinoid therapies have produced early clinical signals in conditions that strongly affect quality of life, making direct quality-of-life research worthwhile.
Medical Cannabis Is Not One Treatment
Another source of confusion is the phrase “medical cannabis” itself. It can refer to radically different interventions.
A purified CBD medicine is not the same exposure as a THC-dominant cannabis flower. An intraoral CBD gel is not equivalent to an edible. A balanced THC-CBD spray behaves differently from a cannabinoid mouthwash. Route of administration, dose, cannabinoid ratio and formulation can all change what reaches the bloodstream and which adverse effects occur.
This matters especially because some of the strongest dentistry-specific human evidence concerns CBD rather than conventional whole-plant cannabis. The acute dental-pain trial, for example, used a pharmaceutical CBD oral solution. The bruxism trial used defined intraoral CBD formulations. Treating those results as evidence for any cannabis product would stretch the studies far beyond what they actually tested.
The same problem appears throughout medical cannabis research. Even CBD and THC can affect one another’s pharmacology, which is why product composition cannot be treated as a minor detail.
Potential Benefits Have to Be Weighed Against Dental Risks
Cannabis and oral health have a complicated relationship. Studying cannabinoids as medicines does not erase evidence that cannabis use can create problems for dental patients.
The American Dental Association’s overview of cannabis and oral health notes concerns including dry mouth, periodontal disease and other oral findings among cannabis users. Acute intoxication presents a separate set of problems in the dental chair because it can affect anxiety, cardiovascular responses and a patient’s ability to provide reliable informed consent. The ADA also highlights possible concerns involving epinephrine-containing local anesthetics in an intoxicated patient.
The 2026 review itself lists xerostomia, dizziness and drowsiness among commonly reported adverse effects. It also discusses drug interactions because CBD and THC can influence liver enzymes responsible for metabolizing other medicines. These issues become particularly relevant for patients taking several drugs at once.
This is one reason the distinction between therapeutic cannabinoid preparations and general cannabis consumption is so important. Research into a controlled CBD gel for jaw pain does not imply that smoking cannabis improves oral health. Those are different exposures with different risk profiles.
What the U.S. Regulatory Picture Means in 2026
The legal environment in the United States changed substantially in April 2026, but not as simply as some headlines suggested. A federal final rule published on April 28, 2026 placed FDA-approved products containing marijuana and marijuana subject to a state medical marijuana license in Schedule III. A separate federal process concerning broader marijuana rescheduling continued afterward. The change did not amount to nationwide legalization of cannabis.
The Cannex has examined why this partial change may make some research easier while leaving major scientific barriers intact in our analysis of marijuana rescheduling and cannabis research.
For dentistry, another distinction is even more important: federal scheduling and FDA approval are not the same thing. According to the FDA’s current cannabis information, the agency has not approved cannabis itself to treat any disease or condition. It has approved specific cannabis-derived or cannabis-related medicines for defined indications. None carries an FDA-approved indication for routine dental pain, bruxism, periodontitis or burning mouth syndrome.
State medical-cannabis programs add another layer. Rules governing eligible conditions, professional scope and patient certification differ by state. The federal shift therefore does not create a single nationwide pathway for dentists to use cannabis therapeutically.
What Better Dentistry Research Would Look Like
The next generation of studies needs to ask narrower questions with much bigger samples.
Instead of testing “cannabis for dentistry,” researchers need trials that specify the condition, molecule, formulation, dose, route and comparator. A useful trial might ask whether a defined CBD formulation improves pain and oral-health-related quality of life in patients with a particular temporomandibular disorder compared with placebo and standard care. Another could examine a standardized topical cannabinoid in a clearly diagnosed oral condition.
Quality of life should be measured directly with validated questionnaires rather than inferred from pain reduction alone. Studies also need longer follow-up. A treatment can look impressive after three hours or 30 days and still prove disappointing when used for months.
Safety deserves equal weight. Dry mouth, sedation, gastrointestinal effects, cognitive effects, drug interactions and the possibility of impaired dental consent are not side notes. They are part of the clinical outcome.
The 2026 review gives this emerging field a useful map. Its 59 included publications show that cannabinoid dentistry is no longer merely hypothetical. There are human randomized trials, mechanistic studies and several plausible applications worth investigating. But the map still contains large blank spaces. For patient quality of life in particular, the evidence is promising enough to justify better trials, not strong enough to declare the question settled.
FAQ
Some cannabinoid treatments have reduced dental or orofacial pain in small controlled trials. The evidence is most specific for particular CBD formulations and doses rather than medical cannabis as a broad category. Larger studies are still needed before researchers can determine where these approaches fit into routine dental care.
No. The review argues that symptom control could improve quality of life, but it did not directly test that outcome in its own patient population or calculate a pooled quality-of-life effect. The conclusion should therefore be understood as a promising clinical hypothesis rather than proof.
No. CBD is one cannabinoid found in cannabis. Medical cannabis can contain CBD, THC and other compounds in very different concentrations and formulations. Results from a purified CBD medicine or a defined CBD gel cannot automatically be applied to whole-plant or THC-rich products.
There is no single nationwide rule giving every U.S. dentist that authority. Professional scope, qualifying conditions and certification rules depend on state law. The 2026 federal scheduling changes also did not create an FDA-approved cannabis treatment for dental conditions, so federal classification should not be confused with a standard dental prescription pathway.
Legal Disclaimer
This article is provided for scientific, journalistic and educational purposes only. It does not constitute medical or legal advice and does not recommend the use of cannabis, CBD or any other cannabinoid product for a dental or medical condition. Cannabis laws, professional-scope rules and product regulations vary by jurisdiction and may change over time.
